KURA ONCOLOGY INC (KURA)
US50127T1097 - Common Stock
Kura Oncology to Participate in Stifel Targeted Oncology Forum
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to...
What's going on in today's after hours session
These stocks are moving in today's after hours session
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
– Company anticipates dosing of KO-2806 in combination with adagrasib in KRASG12C-mutant NSCLC next quarter – – Dose escalation of KO-2806 as a...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to...
Kura Oncology GAAP EPS of -$0.55 in-line (NASDAQ:KURA)
Kura Oncology reported Q4 2023 financial results, stating a GAAP EPS of -$0.55.
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation...
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
– KOMET-008 is evaluating ziftomenib in combination with gilteritinib, FLAG-IDA or LDAC in patients with relapsed/refractory NPM1-mutant or...
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
Kura Oncology files to sell 8.7M shares for its holders (NASDAQ:KURA)
Kura Oncology files prospectus for resale of 8.7 million common shares, clarifying it is not an offer to sell securities.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to...
Noteworthy Tuesday Option Activity: ATGE, ATXS, KURA
Kura Makes Good On Its $150 Million Infusion And Shoots Up Another 15%
The company just released promising results for its acute myeloid leukemia treatment.
Kura Oncology stock jumps after positive preliminary data in leukemia trial (NASDAQ:KURA)
Kura Oncology's stock surges 38% after positive data from trial of investigational drug for acute myeloid leukemia patients.
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
– No differentiation syndrome events reported – – 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML – – 56% CR/CRh with ven/aza in menin...
Kura Oncology Rockets 39% Before Unveiling Cancer Drug Test Results — Here's Why
Kura Oncology is still a week out from unveiling the results for an AML drug. But shares soared Wednesday.
Kura Oncology announces oversubscribed $150 million private placement (NASDAQ:KURA)
Kura Oncology announces oversubscribed private placement, selling shares of its common stock and pre-funded warrants, anticipating gross proceeds of $150...
Kura Oncology Announces Oversubscribed $150 Million Private Placement
– Funding from existing investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta Capital – – Pro forma cash, cash equivalents...
Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
Kura Oncology files for $150M common stock offering, mixed securities shelf (NASDAQ:KURA)
Kura Oncology files for $150M stock offering and mixed securities shelf in a recent prospectus, but it does not include an offer to sell or buy securities.
Kura Oncology GAAP EPS of -$0.50 beats by $0.05 (NASDAQ:KURA)
Kura Oncology beats expectations with Q3 earnings as both research and development expenses and general and administrative expenses surpass previous year's...
Kura Oncology Reports Third Quarter 2023 Financial Results
– Completion of enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML expected by mid-2024 – – Preliminary data from 20...
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
– Ongoing Phase 1 dose-escalation trial of KO-2806 (FIT-001) expected to begin dosing patients in combination with adagrasib by mid-2024 –...